Loading
Adding two years of abiraterone to hormone therapy and radiotherapy for high-risk localised or node-positive prostate cancer halved the risk of metastases and cut deaths by 40 percent, while adding enzalutamide on top brought only extra toxicity.
Meta-analysis of two STAMPEDE comparisons including 1,974 men with high-risk non-metastatic prostate cancer (node-positive, or node-negative with at least two of T3/4, Gleason 8 to 10, PSA 40 or more) randomised to androgen deprivation with or without two years of abiraterone (with enzalutamide in the second comparison).
Six-year metastasis-free survival was 82 versus 69 percent (hazard ratio 0.53) and overall survival 86 versus 77 percent (hazard ratio 0.60); enzalutamide added toxicity without efficacy.
Two years of abiraterone with androgen deprivation and radiotherapy is the standard for very high-risk and node-positive localised prostate cancer.
Shares STAMPEDE, The Lancet.
Shares Abiraterone acetate, Enzalutamide.
Shares STAMPEDE, The Lancet.
Shares Abiraterone acetate, Enzalutamide.
Shares Abiraterone acetate, Enzalutamide.
Shares Abiraterone acetate, Enzalutamide.
Shares Abiraterone acetate, Enzalutamide.
Shares Abiraterone acetate, Enzalutamide.